Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease

Journal of Gastroenterology

Volumn 48, Issue 12, 2013, Pages 1392-1400

  Tokushige, Katsutoshi ^a   Hashimoto, Etsuko ^a   Kodama, Kazuhisa ^a   Tobari, Maki ^a   Matsushita, Noriko ^a   Kogiso, Tomomi ^a   Taniai, Makiko ^a   Torii, Nobuyuki ^a   Shiratori, Keiko ^a   Nishizaki, Yasuhiro ^b   Ohga, Takushi ^c   Ohashi, Yoshiaki ^c   Sato, Takaya ^d  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY TOKYO HOSPITAL   (Japan)

^c Keio University and Human Metabolome Technologies Inc   (Japan)

^d TSURUOKA NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

16 HYDROXYDEHYDROEPIANDROSTERONE SULFATE; BIOLOGICAL MARKER; MITOCHONDRION ANTIBODY; PRASTERONE SULFATE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN METABOLISM; ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIARY CIRRHOSIS; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; JAPANESE; LIQUID CHROMATOGRAPHY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR WEIGHT; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; DISEASE PROGRESSION; ELECTROPHORESIS, CAPILLARY; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, BILIARY; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84891481276     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0766-5     Document Type: Article

References (32)

1. Teli MR, James OFW, Burt AD, Bennet MK, Day CP. The natural history of nonalcoholic fatty liver: follow-up study. Hepatology. 1995;22:1714-9.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis; summary of an AASLD single topic conference. Hepatology. 2003;37:1202-19.
3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-21.
4. Hashimoto E, Farrell GC. Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis? J Gastroenterol Hepatol. 2009;24:501-3.
5. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874-82.
6. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-4.
7. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008;13:389-96.
8. Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S, et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem. 2005;77:4108-16.
9. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation. 2005;112:3868-75.
10. Heazell AE, Brown M, Worton SA, Dunn WB. Review: the effects of oxygen on normal and pre-eclamptic placental tissue-insights from metabolomics. Placenta. 2011;32(Suppl 2):S119-24.
11. Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 2011;60:404-13.
12. Puri P, Wiest MM, Cheung O, Mirsahi F, Sargent C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 2009;50:1827-38.
13. Barr J, Caballeria J, Martinez-Arranz I, Dominguez-Diez A, Alonso C, Muntane J, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res. 2012;6:2512-32.
14. Brunt EM, Janney CG, Di Biscrglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staining the histological lesions. Am J Gastroenterol. 1999;94:2467-74.
15. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3-16.
16. Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver. 1995;15:70-7.
17. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967;60:1257-60.
18. Soga T, Igarashi K, Ito C, Mizobuchi K, Zimmermann HP, Tomita M. Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal Chem. 2009;81:6165-74.
19. Awata N, Yamamoto K, Sugimoto I. Absorption, excretion and metabolism of dehydroepiandrosterone sulfate in rabbits. Yakugaku Zasshi. 1978;98:880-5.
20. Kasumov T, Edmison JM, Dasarathy S, Bennett C, Lopez R, Kalhan SC. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism. 2011;60:776-81.
21. Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008;47:484-92.
22. Bianchi G, Marchesini G, Brunetti N, Manicardi E, Montuschi F, Chianese R, et al. Impaired insulin-mediated amino acid plasma disappearance in non-alcoholic fatty liver disease: a feature of insulin resistance. Dig Liver Dis. 2003;35:722-7.
23. Mong MC, Chao CY, Yin MC. Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet. Eur J Pharmacol. 2011;653:82-8.
24. Kwon do Y, Jung YS, Kim SJ, Park HK, Park JH, Kim YC. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr 2009;139:63-8.
25. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology. 2007;133:608-18.
26. Matsuda Y, Fujita T, Hada T, Higashino K. Comparative study on the correlation of plasma gamma-aminobutyric acid and pipecolic acid with liver function in patients with liver cirrhosis. Hepatol Res. 2000;18:132-40.
27. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol. 2001;145:457-61.
28. Hampl R, Starka L. Mini review: 16-a-hydrpxylated metabolites of dehydroepiandrosterone and their biological significance. Endrocrine Reg. 2000;34:161-3.
29. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem. 1984;20:1077-81.
30. Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology. 2012;55:1282-91.
31. Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44:1196-207.
32. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-4.